• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Geron Corporation

    4/8/22 4:00:27 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GERN alert in real time by email
    SC 13G 1 ea158262-13gvivo_geron.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Geron Corporation

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value

     

    (Title of Class of Securities)

     

    374163103

     

    (CUSIP Number)

     

    April 1, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the

     

     

     

     

     

     

    CUSIP No. 374163103
    1 NAMES OF REPORTING PERSONS
    Vivo Opportunity, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a)     ☐
    (b)     ☐
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    22,857,143 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    22,857,143 (1)
    8 SHARED DISPOSITIVE POWER
    0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    22,857,143 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
    ☐ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.9 % (2)
    12 TYPE OF REPORTING PERSON (See Instructions)
    OO

     

    (1)

    The number of securities includes (i) 15,238,095 shares of common stock, par value $0.001 per share (the “Common Stock”) of Geron Corporation (the “Issuer”) and (ii) 7,619,048 shares of Common Stock issuable upon exercise of certain warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)

    Based on 377,064,925 shares of Common Stock of the Issuer issued and outstanding, as disclosed in the prospectus filed by the Issuer on March 30, 2022, pursuant to Rule 424(b)(5), which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-248637).

     

    2

     

     

    Item 1. (a)Name of Issuer:

     

    Geron Corporation

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    919 E. Hillsdale Boulevard, Suite 250

     

    Foster City, California 94404

     

    Item 2. (a)Name of Person Filing:

     

    Vivo Opportunity, LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

    (c)Citizenship:

     

    Delaware limited liability company.

     

    (d)Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    (e)CUSIP Number:

     

    374163103

     

    Item 3.If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a) ☐Broker or dealer registered under Section 15 of the Act.

     

    (b) ☐Bank as defined in Section 3(a)(6) of the Act.

     

    (c) ☐Insurance company as defined in Section 3(a)(19) of the Act.

     

    (d) ☐Investment company registered under Section 8 of the Investment Company Act of 1940.

     

    (e) ☐An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ☐An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ☐A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

     

    (h) ☐A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i) ☐A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j) ☐A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ☐Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

    3

     

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    (1)Vivo Opportunity, LLC

     

    The 15,238,095 shares of Common Stock and warrants exercisable into 7,619,048 shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The voting members of Vivo Opportunity, LLC are Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

     

    (b)Percent of class:

     

    5.9 %

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: 22,857,143 shares

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of: 22,857,143 shares

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Vivo Opportunity, LLC
       
     

    April 8, 2022

      (Date)
       
      /s/ Gaurav Aggarwal
      (Signature)
       
      Managing Member
      (Title)

     

     

    5

     

     

    Get the next $GERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GERN

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    2/26/2025Buy → Neutral
    H.C. Wainwright
    11/5/2024$8.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$7.00Outperform
    Leerink Partners
    4/30/2024$4.50Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Geron with a new price target

    Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00

    7/10/25 8:55:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron downgraded by Scotiabank with a new price target

    Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

    5/8/25 8:26:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

    2/27/25 6:20:37 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    SEC Filings

    View All

    Geron Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GERON CORP (0000886744) (Filer)

    1/12/26 8:00:26 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Geron Corporation

    8-K - GERON CORP (0000886744) (Filer)

    1/6/26 6:01:15 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - GERON CORP (0000886744) (Filer)

    12/16/25 4:01:36 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.c

    2/11/26 7:27:26 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation Provides 2026 Financial Guidance

    2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, aiming to change lives by changing the course of blood cancer, today announced 2026 financial guidance. "Our priorities for 2026 are clear – driving RYTELO® commercial growth in the U.S., pursuing paths to bring RYTELO to LR-MDS markets outside the U.S., and advancing our P

    1/12/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to purchase an aggregate of 320,000 shares of common stock to one newly hired employee as an inducement material to such employee's acceptance of employment with Geron. The stock options have an exercise price of $1.34 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee

    12/18/25 4:30:00 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    5/13/25 4:20:43 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    3/3/25 6:01:08 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    3/3/25 6:01:06 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Spiegel Robert J. was granted 5,918 shares, increasing direct ownership by 3% to 194,464 units (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    1/5/26 5:40:11 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Commercial Officer Elnawawi Ahmed

    4 - GERON CORP (0000886744) (Issuer)

    10/20/25 5:35:05 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Elnawawi Ahmed claimed ownership of 10,000 shares (SEC Form 3)

    3 - GERON CORP (0000886744) (Issuer)

    10/20/25 5:07:28 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Financials

    Live finance-specific insights

    View All

    Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.c

    2/11/26 7:27:26 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team with appointment of Chief Commercial Officer and additional key executives Announced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting  Company to host conference call and webcast today, November 5, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 an

    11/5/25 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

    Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website. About Geron Geron is a com

    10/27/25 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Geron Corporation Announces Executive Leadership Transitions and Appointments

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commer

    10/13/25 4:34:48 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 9:31:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Geron Corporation

    SC 13G - GERON CORP (0000886744) (Subject)

    11/14/24 6:25:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care